I'm LongbridgeAI, I can summarize articles.Intuitive Surgical dropped 3.98% this week, closing at $378.81 and underperforming the S&P 500 by roughly 2.55 percentage points. The stock swung through a wide 9.72% range, charting a sharp sell-off followed by a modest bounce. After opening Monday at $392.10, the price pushed higher mid-week, touching an intraday high of $405.34 on Wednesday. The tone shifted dramatically on Thursday, when shares tumbled 5.84% to $374.48, hitting a session low of $367.24.
The Week
Intuitive Surgical dropped 3.98% this week, closing at $378.81 and underperforming the S&P 500 by roughly 2.55 percentage points. The stock swung through a wide 9.72% range, charting a sharp sell-off followed by a modest bounce. After opening Monday at $392.10, the price pushed higher mid-week, touching an intraday high of $405.34 on Wednesday. The tone shifted dramatically on Thursday, when shares tumbled 5.84% to $374.48, hitting a session low of $367.24. Friday saw a partial recovery to $378.81, though the stock remained well below its pre-sell-off levels.
Key Events
Intuitive Surgical announced a new manufacturing facility in Penang, Malaysia, expanding its production footprint in Asia Pacific. The week also saw a cluster of insider sales: EVP and Chief Manufacturing and Supply Chain Officer Mark Brosius sold a combined 462 shares across three separate transactions, totalling roughly $210,000. While the dollar amounts are negligible against the company’s $133.8 billion market cap, the pattern of disposals drew attention amid the week’s sharp price swing. Separately, several media outlets highlighted that Intuitive Surgical is on track for its worst annual performance since 2008, adding to the narrative of a stock under pressure.
Analyst Ratings
Of the 33 brokers covering the stock, 17 rate it a buy, 7 rate it overweight, 8 rate it hold, and 1 rates it sell. The consensus recommendation stands at ‘buy’, with a consensus target price of $478.01, implying a roughly 26.2% upside from current levels. Individual target prices range from $324 to $685, a wide spread that signals divergent views on the company’s long-term trajectory. Intuitive Surgical ranks first among 140 peers in the medical devices industry by broker rating.
The Week Ahead
No major company-specific events are scheduled, so the focus shifts to the macro calendar. On Tuesday, 25 August, the US will release a batch of housing data—including the FHFA House Price Index, the Case-Shiller 20-City Index, and new home sales—alongside consumer confidence figures. These prints will offer clues on how the rate environment is feeding through to asset prices and sentiment, which could indirectly colour the valuation outlook for high-multiple growth names like Intuitive Surgical.
In Short
This week painted a mixed picture for Intuitive Surgical. The broker consensus remains firmly buy-rated, with a target price that sits comfortably above spot, yet the stock shed nearly 4% and saw a volume spike on Thursday’s rout. Insider selling and growing chatter about the worst year since 2008 add a layer of sentiment friction. At around 42.6x trailing earnings, the stock does not screen as cheap within the medical devices space. The near-term direction likely hinges on whether upcoming macro data can steady the valuation narrative for growth equities.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.